Skip to content

Clovis up on rucaparib data in prostate cancer

August 17, 2020

Clovis Oncology (CLVS +19.5%) jumps on more than double normal volume on the heels of additional data from the Phase 2 TRITON2 study evaluating Rubraca (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC) patients harboring BRCA1/2 mutations. The results, supporting accelerated approval in the U.S. three months ago for this indication, were just published online in the Journal of Clinical Oncology.

Confirmed objective response rate (ORR) per independent radiology review was 43.5% – 56.7%. ORR via investigator assessment was 50.8% – 63.4%.

Confirmed PSA response rate was 54.8%.

On the safety front, the most frequent serious or higher treatment-emergent adverse event was anemia (25.2%).

Related tickers: AstraZeneca (AZN +2.3%), Merck (MRK +1.9%)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: